Carbohydrate-based anti-inflammatories - Praxis/Fairchild

Drug Profile

Carbohydrate-based anti-inflammatories - Praxis/Fairchild

Latest Information Update: 31 May 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Anutech
  • Developer Anutech; Praxis Pharmaceuticals
  • Class Carbohydrates
  • Mechanism of Action Insulin-like growth factor II stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Diabetes mellitus; Multiple sclerosis; Ocular inflammation; Post-surgical adhesions; Psoriasis; Rheumatoid arthritis; Skin aging

Most Recent Events

  • 01 Aug 2001 This programme is still in active development for the management of facial wrinkles
  • 24 Nov 1999 Investigation in Diabetes mellitus in Australia (PO)
  • 24 Nov 1999 Investigation in Multiple sclerosis in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top